Oppenheimer analyst, Christopher Marai, anticipates a narrowly positive BioMarin (NASDAQ: BMRN) Kyndrisa panel outcome, and discussion highlighting key differentiation of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA Hot Comments

Oppenheimer Sees Hints of Accelerated Approval for BioMarin Pharma (BMRN) KyndrisaNovember 23, 2015 7:53 AM BioMarin (BMRN) PT Trimmed at Wedbush Following Briefing Docs; Sees Positive Read-Thru to SRPT, None to PTCTNovember 20, 2015 12:33 PM PTC Completes Enrollment of Phase 3 Clinical Trial of Translarna™ for Patients with Cystic FibrosisNovember 19, 2015 8:00 AM Jefferies Survey Suggests Positive Expectations for BioMarin (BMRN) Ahead of Data on 11/24November 19, 2015 7:42 AM